Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
about
Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial SurgeonsNew dimensional staging of bisphosphonate-related osteonecrosis of the jaw allowing a guided surgical treatment protocol: long-term follow-up of 266 lesions in neoplastic and osteoporotic patients from the university of bari.A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosisPhase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancerIs bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled studyBisphosphonate-related osteonecrosis of the jaw: historical, ethical, and legal issues associated with prescribing.Updates on osteonecrosis of the jawOsteonecrosis of the jaw and bevacizumab therapy.A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer.Distinctive tooth-extraction socket healing: bisphosphonate versus parathyroid hormone therapy.HIF targets in bone remodeling and metastatic disease.Diabetes as a risk factor for medication-related osteonecrosis of the jaw.Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process.Bone metabolism and clinical study of 44 patients with bisphosphonate-related osteonecrosis of the jaws.Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists.The anti-tumour effects of zoledronic acidThe changing landscape in the treatment of metastatic castration-resistant prostate cancer.Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection.Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.Castrate-resistant prostate cancer: therapeutic strategies.Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.Managing bone health with zoledronic acid: a review of randomized clinical study results.Bevacizumab treatment of prostate cancer.Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents.New cancer therapies and jaw necrosis.Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology.Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience.Metronomic treatment with low-dose trofosfamide leads to a long-term remission in a patient with docetaxel-refractory advanced metastatic prostate cancerBevacizumab-related osteneocrosis of the jaw.Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab.Long-term treatment with intravenous bisphosphonates in metastatic breast cancer: a retrospective study.Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis.Nitric oxide donors improve prednisone effects on muscular dystrophy in the mdx mouse diaphragm.Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.Osteonecrosis of the Jaw among Patients Receiving Antiresorptive Medication: A 4-year Retrospective Study at a Tertiary Cancer Center, Kerala, India.Diabetes Mellitus and Its Association to the Occurrence of Medication-Related Osteonecrosis of the Jaw.Bisphosphonate-related osteonecrosis of the jaw: a mechanobiology perspective.Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma.
P2860
Q26771715-4105741B-CDF1-41BE-9D37-F9C57AE95874Q33796816-816F2C8A-79BC-4085-AB17-1B27024E7233Q33810748-6CC84448-0E63-44BA-9527-958AC99E39FDQ33813626-21D9A47E-A5E9-4EBD-9054-9E43A46B3968Q33866456-CB2E0E1A-16AB-4A07-A578-973E062D5A5AQ33885770-93ABBA9D-7350-4ADA-8986-54786E5ED072Q34234108-200076CC-EE48-4B15-AB62-753B065F3473Q34287614-97E8EA1C-3C85-4CC0-91DF-74F6244EC840Q34392792-20313865-4760-4DA3-A75C-880E04F6EC76Q34575759-D77731ED-5C0A-469A-B6DA-0C2F14B1ED73Q35554344-06BBD6D0-7202-4385-82F7-16D86C569834Q35627669-058BD469-A77E-4386-AF22-774175744B02Q35978414-B58BC706-F37F-41EC-9F01-49FC29CBE6A9Q36421443-6415FE63-BC84-409D-B6B6-901DC2A8A033Q36491413-DAD61E24-78A1-4423-BE34-D2B4516A245BQ36491653-6DA15800-C345-4F5E-B354-C4710E276071Q36515526-2C755243-DDC6-4E49-92DE-0FF0D617247AQ36553506-CDE59B73-0DA3-4E1A-8D35-E332621DED7EQ37166534-90952E84-EB86-4F17-B36E-4DC7AE52188CQ37181561-458AA506-D2CF-4D28-AD4B-52ABE2703828Q37577926-296EAC49-2131-4CD4-BD80-392B5ACACA20Q37716009-C6A2E81A-DF11-4551-B9A4-F3FAB4AF5EE9Q37800176-F43C40A2-F902-4EF0-B6D0-B55AF006762EQ37823605-40443755-89E7-486F-BC40-A27B70233FB3Q38024852-8FF6FFDC-13CE-453B-A052-F31D3666072EQ38184580-B815F64A-F7EF-4DC8-A4C8-95DFCCB71653Q38584982-2788483F-4DC0-4BB3-88EC-E21322FF16FAQ38807483-2655D749-E284-493F-80A1-3A136D1D2F46Q38845259-1252CA94-2B0E-49D1-8E4B-61BB025C2A26Q40002385-D9AB0663-2CDF-4F62-AD5D-E83416474BD0Q43194447-E88E3928-0C9C-42AC-9769-B228254F2597Q46535211-7D37BB75-DE36-46E1-89C2-9BE1BA68F7A9Q46691665-4E7F24A4-B644-4ADD-AC94-5DB66525C88CQ46949164-37FF2173-A73A-4276-81B8-0AEF41CF9B09Q50283542-29ED9E04-91A8-4D3C-9757-6AF7E67EE406Q51522929-BE34BA30-F4D4-4317-AF0C-56E1850C7969Q52620697-D0DC1EB4-83ED-41FC-969A-2E0725B71367Q55075852-739DA18B-493D-4066-8B48-7F362D6187F0Q55364153-8BB2872C-A0A4-45E0-B683-0CF63BDFA42EQ55384058-ABFE8236-29AC-415F-8221-D4D2121BEF2E
P2860
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Higher incidence of Osteonecro ...... d with anti-angiogenic agents.
@en
Higher incidence of Osteonecrosis of the Jaw
@nl
type
label
Higher incidence of Osteonecro ...... d with anti-angiogenic agents.
@en
Higher incidence of Osteonecrosis of the Jaw
@nl
prefLabel
Higher incidence of Osteonecro ...... d with anti-angiogenic agents.
@en
Higher incidence of Osteonecrosis of the Jaw
@nl
P2093
P2860
P1433
P1476
Higher incidence of Osteonecro ...... ed with anti-angiogenic agents
@en
P2093
Clara C Chen
Howard Parnes
James L Gulley
Jean-Pierre Guadagnini
John J Wright
Lea Latham
Philip M Arlen
William D Figg
William L Dahut
Yang-Min Ning
P2860
P304
P356
10.1080/07357900802208608
P577
2009-02-01T00:00:00Z